Role of integrase inhibitors in the treatment of HIV disease

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 1, 2007, Pages 67-75

  Palmisano, Lucia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Antiviral resistance; HAART; HIV infection; HIV RNA; Integrase; Integrase inhibitors

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; BETA DIKETOACID DERIVATIVE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; FZ 41; GS 9137; GSK 810871; INTEGRASE INHIBITOR; JTK 303; L 708906; L 870812; L 900612; LAMIVUDINE; LIPID; MK 0518; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NAPHTHYRIDINE DERIVATIVE; PLACEBO; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG UTILIZATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME STRUCTURE; FOOD; FOOD DRUG INTERACTION; GENE MUTATION; GENETIC CODE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIFE CYCLE; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MUTATIONAL ANALYSIS; NEUROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; PHARMACOGENETICS; REVIEW; SIDE EFFECT; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; DRUG EFFECT; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; METHODOLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS;

EID: 33947715164     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.1.67     Document Type: Review

References (47)

1. Fischl MA, Richman DD, Grieco MH et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 185-191 (1987).
2. Delta coordinating committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348, 283-291 (1996).
3. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337, 725-733 (1997).
4. Walensky RP, Paltiel AD, Losina E. The survival benefits of AIDS treatment in the United States. J. Infect. Dis. 194, 11-19 (2006).
5. Vella S, Palmisano L. The global status of resistance to antiretroviral drugs. Clin. Infect. Dis. 41 (Suppl. 4), S239-S246 (2005).
6. Kitamura Y, Ayukawa T, Ishikawa T, Kanda T, Yoshiike K. Human endogenous retrovirus K10 encodes a functional integrase. J. Virol. 70, 3302-3306 (1996).
7. Rice PA, Baker TA. Comparative architecture of transposases and integrase complexes. Nature Struct. Biol.. 8, 302-307 (2001).
8. Jacque JM, Stevenson M. The innernuclear-envelope protein emerin regulates HIV-1 infectivity. Nature 441, 641-645 (2006).
9. Liu H, Dow C E, Arora R et al. Integration of human immunodeficiency virus type 1 in untreated infection occurs preferentially within genes. J. Virol. 80, 7765-7768 (2006).
10. Cara A, Reitz MS. New insight on the role of extrachromosomal retroviral DNA. Leukemia 11, 1395-1398 (1997).
11. Sharkey, ME, Teo L, Greenough T et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nat. Med. 6, 76-81 (2000).
12. McDermott J L, Martini I, Ferrari D et al. Decay of human immunodeficiency virus type 1 unintegrated DNA containg two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia. J. Clin. Microbiol., 43, 5272-5274 (2005).
13. Chu TK, Davies DR. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 4, 965-977 (2004).
14. Lu R, Limon A, Ghory HZ, Engelman A. Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase. J. Virol. 79, 2493-2505 (2005).
15. Chow SA, Vincent KA, Elison V, Brown PO. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 255, 723-726 (1992).
16. Fesen MR, Kohn KW, Lefeurtre F, Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc. Nat. Acad. Sci. USA 90, 2399-2403 (1993).
17. Craigie R, Mizuuchi K, Bushman FD, Engelman A. A rapid in vitro assay for HIV DNA integration. Nucleic Acids Res. 19, 2729-2734 (1991).
18. Hazuda DJ, Hastings JC, Wolf AL, Emini EA. A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res.. 22, 1121-1122 (1994).
19. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/ AIDS. Nat. Rev. Drug Discovery 4, 236-248 (2005).
20. Goldgur Y, Craigie R, Cohen GH et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl Acad. Sci. USA 96, 13040-13043 (1999).
21. Hazuda D, Felock P, Wilmer M et al. Inhibitors of strand transfer that prevent integration and inhibit HIV replication in cells. Science 287, 646-650 (2000).
22. Grobler JA, Stillmock K, Hu B et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl Acad. Sci. USA 99, 6661-6666 (2002).
23. Fikkert V, Van Maele B, Vercammen J et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol. 77, 11459-11470 (2003).
24. Hazuda D, Anthony NJ, Gomez RP et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl Acad. Sci. USA 101, 11233-11238 (2004).
25. Hazuda DJ, Young SD, Guare JP et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305, 528-532 (2004).
26. Embrey MW, Way JS, Funk TW et al. A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6] naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg. Med. Chem. Lett. 15, 4550-4554 (2005).
27. Sato M, Motomura T, Aramaki H et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 49, 1506-1508 (2006).
28. Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Investig. Drugs 4, 206-209 (2003).
29. Mousnier A, Leh H, Nouscadet JF, Dergemont C. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol. Pharmacol. 66, 783-788 (2004).
30. Little S, Drusano C, Schooley R et al. Antiretroviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1-infected patients. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infection. MA, USA, February 22-25 Abstr. 161 (2005).
31. Markowitz M, Morales-Ramirez JO, Nguyen B-J et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment- naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43, 509-515 (2006).
32. Grinsztejn B, Nguyen BY, Katlama C et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inihibitor, in patients with triple-class resistant virus. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infection. CO, USA February 5-8 Abstr. 159LB (2006).
33. Grinsztejn B Nguyen BY, Katlama C et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple class resistant virus. Proceedings of the 46th ICAAC, CA, USA, September 27-30, Abstr. H-1670b (2006).
34. Markowitz M, Nguyen B-Y, Gotuzzo F et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment naive HIV-1 infected patients. Proceedings of the XVI Internatinal AIDS Conference, Toronto (Canada) August 13-18, Abstr. THLB0214 (2006).
35. Iwamoto M, Wenning LA, Petry SA et al. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (OK) of MK0-518. Proceedings of the 46th ICAAC, San Francisco (CA) September 27-30, Abstr. A-373 (2006).
36. Wenning LA, Hanley H, Stone J et al. Effect of tipranavir + ritonavir (tpv + rtv) on pharmacokinetics of MK-0518. Proceedings of the 46th ICAAC, CA, USA, September 27-30, Abstr. A-374 (2006).
37. Wenning LA, Friedman E Kost JT. Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate (TDF). Proceedings of the 46th ICAAC, CA, USA September 27-30, Abstr. A-375 (2006)
38. DeJesus E, Berger D, Markowitz M et al. Antiviral activity, pharmacokinetics, and dose response of the HIV integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43, 1-5 (2006).
39. Winston A, Hales G, Amin J et al. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. AIDS 19, 1393-1399 (2005).
40. Fikkert V, Hombrouck A, Van Remoortel B et al. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 18, 2019-2028 (2004).
41. Hazuda DJ and the MRL HIV-1 Drug Discovery Team. Context dependent effects of mutations associated with resistance to inhibitors of HIV-1 integrase strand transfer. Antiviral Ther. 10, S82, (2005).
42. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antiviral Ther. 11, S28 (2006).
43. Fransen S, Gupta S, Paxinos E et al. Natural variation in susceptibility of patient-derived HIV-1 to an integrase strand transfer inhibitor. Antiviral Ther. 11, S27 (2006).
44. Di Santo R, Costi R, Roux A et al. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities and mechanism of actions. J. Med. Chem. 49, 1939-1945 (2006).
45. Dupuis ML, Cianfriglia M, Costi R et al. HIV-1 Integrase Inhibitors Are Potent Sustrates for the MDR1 Multidrug Transporter. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections. CO, USAFaebruary 5-8 Abstr. 565 (2006).
46. Tsibris AM, Kuritzkes DR. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med. 58, 445-459 (2007).
47. + T cells: a barrier to cure. Curr. Opin. HIV AIDS 1, 121-128 (2006).